Halozyme Therapeutics | HALO - Net Income


Halozyme Therapeutics reported $229.91M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 2.38B 556M Jun/2026
Baxter International USD 126M 141M Jun/2026
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Cytokinetics USD -198.76M 7.27M Jun/2026
DBV Technologies USD -47.6M 2.77M Mar/2026
Eli Lilly USD 7.1B 301M Jun/2026
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
MannKind USD -16.62M 671K Mar/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Pfizer USD -248M 2.94B Jun/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
United Therapeutics USD 333M 58.1M Jun/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024